Please assess the completion status of the following clinical trial:

Trial Title: Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to comprehend and sign an informed consent~2. Aged 18 years or more~3. Histologically or cytologically-confirmed metastatic adenocarcinoma of the colon and/or rectum~4. Measurable disease according to the RECIST criteria~5. Eastern Cooperative Oncology Group (ECOG) status of 0-2~6. Non-mutated k-ras gene (k-ras status will be assessed by DNA sequencing in codons 12 and 13)~7. Haematologic function: ANC \>1.5 x 109/L, Leucocyte count \>3000/mm3, Haemoglobin \>10g/ d L, PLT \>100 x 109/ L~8. Renal function: serum creatinine ≤1.5xUNL or creatinine clearance \> 50ml/min~9. Hepatic function:~   * Total bilirubin ≤ 1.5 time the upper normal limit (UNL)~  * ASAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL in presence of liver metastases~  * ALAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL in presence of liver metastases~10. Metabolic function:~    * Magnesium ≥ lower limit of normal.~   * Calcium ≥ lower limit of normal.~Exclusion Criteria:~1. Central nervous system metastases~2. Prior therapy for metastatic disease~3. Adjuvant chemotherapy for the last 6 months~4. Prior anti-EGFR therapy or treatment with EGFR tyrosine kinase inhibitors~5. Prior radiotherapy within 30 days from enrollment~6. Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) \<=1 year before enrollment~7. History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.~8. Inflammatory bowel disease or chronic diarrhea~9. Dihydropyrimidine deficiency~10. Positive test for HIV infection, hepatitis C infection, chronic active hepatitis B infection~11. Any kind of disorder compromising the ability of the patient to give informed consent~12. Any investigational agent within 30 days prior to initiation of the study~13. Any surgical procedure within 28 days prior to initiation of the study~14. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.~15. Female subject in childbearing age with a positive pregnancy test at screening or before initiation of study treatment.~16. Subject (male or female) not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Panitumumab,capecitabine,oxaliplatin (Type: EXPERIMENTAL): Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg.~Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 Capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14

Based on this trial design, predict the completion outcome and termination type (if applicable).